oxford immunotec appoints richard wenstrup md as chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       oxford immunotec oxfd appoints richard wenstrup md as chief medical officer tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs oxford united kingdom and marlborough mass july   globe newswire  oxford immunotec global plc nasdaqoxfd a global highgrowth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immuneregulated conditions today announced the appointment of richard wenstrup md as chief medical officer dr wenstrup brings to oxford immunotec more than  years of clinical leadership experience including over a decade within the diagnostics industry most recently dr wenstrup served as executive vice president chief medical officer for myriad genetics inc where he played a key leadership role and made substantial contributions across the company that helped drive and support a multifold increase in revenue over a decade in addition to building and leading myriad’s clinical and medical affairs teams dr wenstrup was actively involved in the company’s product development ma and inlicensing activities he also previously served as chief medical officer for myriad genetic laboratories inc “we are extremely pleased to welcome rick to the team during this exciting time at oxford immunotec” said ceo dr peter wrightonsmith “rick’s extensive leadership experience and the depth and breadth of his clinical scientific and commercial expertise will be immensely valuable as we continue to grow our core tuberculosis franchise and launch products into the new markets of tickborne diseases blood screening and transplantation” prior to joining myriad genetics dr wenstrup served as a tenured professor of pediatrics human genetics at cincinnati children’s hospital medical center and as a tenured professor of biomedical engineering at the university of cincinnati during his time in academia dr wenstrup was principal investigator on multiple research grants from the national institutes of health nih and the fda orphan products grant program he also served as a standing member of nih review committees and on the scientific advisory boards of several diseaserelated foundations dr wenstrup was the founding director of the molecular diagnostics laboratory at cincinnati children’s hospital and cofounder of assurex health inc now a subsidiary of myriad genetics inc about oxford immunotec oxford immunotec global plc is a global highgrowth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immuneregulated conditions the companys first product is the tspot®tb test which is used to test for tuberculosis infection the tspottb test has been approved for sale in over  countries including the united states where it has received premarket approval from the food and drug administration europe where it has obtained a ce mark as well as japan and china the companys second product line is a range of assays for tickborne diseases such as lyme disease obtained through the acquisitions of imugen and immunetics also obtained through the acquisitions is the companys third product line focused on screening for babesia in donated blood for which the company is currently seeking fda licensure the tspotcmv test and the tspotprt test are pipeline products as part of the companys fourth intended product line focused on the transplantation market in addition to these four product lines the company has additional active development programs in other immuneregulated conditions the company is headquartered near oxford uk and in marlborough mass additional information can be found at wwwoxfordimmunoteccom tspot and the oxford immunotec logo are trademarks of oxford immunotec ltd immunetics is a trademark of immunetics inc contacts for media and investor inquiries karen koski head of strategy and investor relations oxford immunotec tel    kkoskioxfordimmunoteccom mark klausner westwicke partners tel    oxfordimmunotecwestwickecom read at biospacecom related news oxford immunotec oxfd schedules second quarter  earnings release and conference call for august   how astrazeneca plc azns silence led to a  billion loss overnight oxford immunotec oxfd schedules second quarter  earnings release and conference call for august   expanding his medical empire is good for patrick soonshiong but is it good for patients oxford immunotec oxfd announces favorable claim construction ruling in patent infringement litigation astrazeneca plc azn ceo breaks silence on teva teva rumors urges staff to remain focused in leaked memo oxford immunotec oxfd names karen koski head of strategy and investor relations glaxosmithkline gsk poaches another top exec—this time from pfizer pfe oxford immunotec oxfd schedules first quarter  earnings release and conference call for may   retired celgene celg alum lands chairman gig at biotech guru ramaswamys dermavant please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • oxford immunotec limited   • biotechpharma  personnel • biotechpharma  personnel world                 oxford immunotec appoints richard wenstrup md as chief medical officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street oxford immunotec appoints richard wenstrup md as chief medical officer globenewswire jul    am edt about oxford immunotec oxford immunotec global plc is a global highgrowth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immuneregulated conditions  the companys first product is the tspot ® tb test which is used to test for tuberculosis infection  the tspot tb test has been approved for sale in over  countries including the united states where it has received premarket approval from the food and drug administration europe where it has obtained a ce mark as well as japan and china  the companys second product line is a range of assays for tickborne diseases such as lyme disease obtained through the acquisitions of imugen and immunetics  also obtained through the acquisitions is the companys third product line focused on screening for babesia in donated blood for which the company is currently seeking fda licensure  the tspot cmv test and the tspot prt test are pipeline products as part of the companys fourth intended product line focused on the transplantation market  in addition to these four product lines the company has additional active development programs in other immuneregulated conditions  the company is headquartered near oxford uk and in marlborough mass  additional information can be found at  wwwoxfordimmunoteccom tspot and the oxford immunotec logo are trademarks of oxford immunotec ltd  immunetics is a trademark of immunetics inc contacts for media and investor inquiries karen koski head of strategy and investor relations oxford immunotec tel    kkoskioxfordimmunoteccom mark klausner westwicke partners tel    oxfordimmunotecwestwickecom if you liked this article you might like insider trading alert  zoes oxfd and lfus traded by insiders stocks with insider trader activity include zoes oxfd and lfus thestreet wire jun    am edt insider trading alert  pbip apol and oxfd traded by insiders stocks with insider trader activity include pbip apol and oxfd thestreet wire jun    am edt insider trading alert  oxfd cswc and cvs traded by insiders stocks with insider trader activity include oxfd cswc and cvs thestreet wire jun    pm edt insider trading alert  oxfd cswc and cvs traded by insiders stocks with insider trader activity include oxfd cswc and cvs thestreet wire jun    pm edt trending ftc seen as set to block rite aid deal tesla ceo elon musk we are going to be in production hell for  months it would be crazy to clean house at wells fargo ceo says the  absolutely cheapest places to buy a house in america  foods to avoid if you have high cholesterol advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft oxford immunotec appoints richard wenstrup md as chief medical officer  oxford immunotec north america home products  services tspot®tb tspot®cmv tspot®prt tcell xtend® testing services science technology product pipeline clinical studies investigator initiated studies medical education applying for a grant company about us our vision our values management team board of directors news  events news industry events awards  recognition in the media investors join our team harnessing the power of t cell measurement contact us contact us office locations worldwide distributors back oxford immunotec appoints richard wenstrup md as chief medical officer oxford united kingdom and marlborough mass july   globe newswire — oxford immunotec global plc nasdaqoxfd a global highgrowth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immuneregulated conditions today announced the appointment of richard wenstrup md as chief medical officer dr wenstrup brings to oxford immunotec more than  years of clinical leadership experience including over a decade within the diagnostics industry most recently dr wenstrup served as executive vice president chief medical officer for myriad genetics inc where he played a key leadership role and made substantial contributions across the company that helped drive and support a multifold increase in revenue over a decade in addition to building and leading myriad’s clinical and medical affairs teams dr wenstrup was actively involved in the company’s product development ma and inlicensing activities he also previously served as chief medical officer for myriad genetic laboratories inc “we are extremely pleased to welcome rick to the team during this exciting time at oxford immunotec” said ceo dr peter wrightonsmith “rick’s extensive leadership experience and the depth and breadth of his clinical scientific and commercial expertise will be immensely valuable as we continue to grow our core tuberculosis franchise and launch products into the new markets of tickborne diseases blood screening and transplantation” prior to joining myriad genetics dr wenstrup served as a tenured professor of pediatrics human genetics at cincinnati children’s hospital medical center and as a tenured professor of biomedical engineering at the university of cincinnati during his time in academia dr wenstrup was principal investigator on multiple research grants from the national institutes of health nih and the fda orphan products grant program he also served as a standing member of nih review committees and on the scientific advisory boards of several diseaserelated foundations dr wenstrup was the founding director of the molecular diagnostics laboratory at cincinnati children’s hospital and cofounder of assurex health inc now a subsidiary of myriad genetics inc about oxford immunotec oxford immunotec global plc is a global highgrowth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immuneregulated conditions the company’s first product is the tspot®tb test which is used to test for tuberculosis infection the tspottb test has been approved for sale in over  countries including the united states where it has received premarket approval from the food and drug administration europe where it has obtained a ce mark as well as japan and china the company’s second product line is a range of assays for tickborne diseases such as lyme disease obtained through the acquisitions of imugen and immunetics also obtained through the acquisitions is the company’s third product line focused on screening for babesia in donated blood for which the company is currently seeking fda licensure the tspotcmv test and the tspotprt test are pipeline products as part of the company’s fourth intended product line focused on the transplantation market in addition to these four product lines the company has additional active development programs in other immuneregulated conditions the company is headquartered near oxford uk and in marlborough mass additional information can be found at wwwoxfordimmunoteccom tspot and the oxford immunotec logo are trademarks of oxford immunotec ltd  immunetics is a trademark of immunetics inc contacts for media and investor inquiries karen koski head of strategy and investor relations oxford immunotec tel    kkoskioxfordimmunoteccom mark klausner westwicke partners tel    oxfordimmunotecwestwickecom   richard j wenstrup addedit   you are here scientific experts  usa  cincinnati childrens hospital medical center  wenstrup  richard j wenstrup research topicscollagen type vehlers danlos syndromeextracellular matrixcell culture techniquesbeta glucosidasealendronatedermisgenotypecollagengaucher diseaseheterozygoteembryolumbar vertebraecollagen type iexonselectron microscopypolyacrylamide gel electrophoresisbiomechanicsskinlongitudinal studiesallelesfibroblastsgenetic vectorsgenetic modelstransgenic micecombination drug therapyin situ hybridizationdouble blind methodbone densitydnagenomes and genescola productscola productscola productscola productscola productscola productstype i collagen productscola productsspeciesmousehumanrichard j wenstrupsummaryaffiliation cincinnati childrens hospital medical centercountry usapublications gaucher disease alendronate disodium improves bone mineral density in adults receiving enzyme therapyrichard j wenstrupdivision of human genetics children s hospital research foundation ml  cincinnati oh   usablood   reduced type i collagen utilization a pathogenic mechanism in cola haploinsufficient ehlersdanlos syndromerichard j wenstrupdivision of human genetics children s hospital research foundation cincinnati ohio   usaj cell biochem   type v collagen controls the initiation of collagen fibril assemblyrichard j wenstrupdivision of human genetics cincinnati children s hospital research foundation  burnet ave ml  cincinnati oh  usaj biol chem   murine model of the ehlersdanlos syndrome cola haploinsufficiency disrupts collagen fibril assembly at multiple stagesrichard j wenstrupdivision of human genetics cincinnati children s hospital research foundation cincinnati ohio  usaj biol chem   colva and colxia are required for myocardial morphogenesis and heart valve developmentjoy lincolndivision of molecular cardiovascular biology cincinnati children s hospital medical center cincinnati ohio  usadev dyn   a genetic approach to fracture epidemiology in childhoodbrad t tinkledivision of human genetics cincinnati children s hospital medical center oh  usaam j med genet c semin med genet   endogenously expressed multimeric selfcleaving hammerhead ribozymes ablate mutant collagen in cellulobelinda e peacecincinnati children s hospital research foundation ml  cincinnati oh   usamol ther   effect of enzyme replacement therapy with imiglucerase on bmd in type  gaucher diseaserichard j wenstrupcincinnati children s hospital research foundation ohio usaj bone miner res   prevalence of aortic root dilation in the ehlersdanlos syndromerichard j wenstrupdivision of human genetics children s hospital research foundation cincinnati oh   usagenet med   structural abnormalities of the cornea and lid resulting from collagen v mutationsfani segevdepartment of ophthalmology and vision sciences the hospital for sick children toronto ontario canadainvest ophthalmol vis sci  collaboratorsjoy lincolnkatherine e yutzeyeric w brunskillsheila m bellwilliam g colebelinda e peacepaige kaplanwei wualan e oestreichgeorge wuari zimrangregory m pastorest n hangartnermarcia c willingiris schrijveralvaro n monteirobrad tinklemaimoona a zariwalafergus joseph couchbai lin wug a grabowskikristina allenbradydouglas f eastoncharlotte phillipselise heondavid e goldgargirish v putchafani segevlinda jo bone jengnancy carsonmarcy l hoffmannfred schaeferjulie m gastierfosterbassem a bejjaniwilliam k seltzermargaret a kennastacey withrowmelissa a dempseyishrag khababamichelle a springerjessica k bookersoma dasiris m otanijohn c careystacey bleookaren e weckkasinathan muralidharanmargaret lilleyelaine b spectorrong maoheidi l rehmjohn h greinwaldinna chervonevaallan r slomovicdavid s rootmandiana whitakermenezesdavid e birkfelix young detail informationpublications gaucher disease alendronate disodium improves bone mineral density in adults receiving enzyme therapyrichard j wenstrupdivision of human genetics children s hospital research foundation ml  cincinnati oh   usablood  alendronate is a useful adjunctive therapy in combination with enzyme replacement therapy ert for the treatment of gdrelated osteopenia in adults but it cannot be expected to improve focal lesions reduced type i collagen utilization a pathogenic mechanism in cola haploinsufficient ehlersdanlos syndromerichard j wenstrupdivision of human genetics children s hospital research foundation cincinnati ohio   usaj cell biochem  these data indicate that in cell culture the quantity of collagen fibrils deposited in matrix is highly sensitive to reduction in type v collagen far out of proportion to type v collagens contribution to collagen mass type v collagen controls the initiation of collagen fibril assemblyrichard j wenstrupdivision of human genetics cincinnati children s hospital research foundation  burnet ave ml  cincinnati oh  usaj biol chem  in addition this fibril collagen is important in the determination of fibril structure and matrix organization murine model of the ehlersdanlos syndrome cola haploinsufficiency disrupts collagen fibril assembly at multiple stagesrichard j wenstrupdivision of human genetics cincinnati children s hospital research foundation cincinnati ohio  usaj biol chem  therefore abnormal fibril nucleation and dysfunctional fibril growth with potential disruption of celldirected fibril organization leads to the connective tissue dysfunction associated with eds colva and colxia are required for myocardial morphogenesis and heart valve developmentjoy lincolndivision of molecular cardiovascular biology cincinnati children s hospital medical center cincinnati ohio  usadev dyn   a genetic approach to fracture epidemiology in childhoodbrad t tinkledivision of human genetics cincinnati children s hospital medical center oh  usaam j med genet c semin med genet   endogenously expressed multimeric selfcleaving hammerhead ribozymes ablate mutant collagen in cellulobelinda e peacecincinnati children s hospital research foundation ml  cincinnati oh   usamol ther  a reversion to a more normal collagen phenotype measured as an increase in fibril diameter and restored fibrillar architecture and a decreased rate of collagen turnover were seen in cells expressing the ribozyme multimer effect of enzyme replacement therapy with imiglucerase on bmd in type  gaucher diseaserichard j wenstrupcincinnati children s hospital research foundation ohio usaj bone miner res  data were analyzed for  untreated patients and  erttreated patients imiglucerase significantly improves bmd in patients with gd with  years of ert leading to normal bmd prevalence of aortic root dilation in the ehlersdanlos syndromerichard j wenstrupdivision of human genetics children s hospital research foundation cincinnati oh   usagenet med  to determine the prevalence of proximal aortic abnormalities in patients with ehlersdanlos syndrome eds structural abnormalities of the cornea and lid resulting from collagen v mutationsfani segevdepartment of ophthalmology and vision sciences the hospital for sick children toronto ontario canadainvest ophthalmol vis sci  the purpose of this study was to define the ocular phenotype resulting from mutations in the type v collagen genes cola and cola and to study the pathogenesis of anomalies in a coladeficient mouse a multicenter study of the frequency and distribution of gjb and gjb mutations in a large north american cohortgirish v putchadepartment of pathology stanford university school of medicine stanford california  usagenet med   a systematic genetic assessment of  sequence variants of unknown clinical significance in the brca and brca breast cancerpredisposition genesdouglas f eastongenetic epidemiology unit strangeways research laboratories university of cambridge cambridge ukam j hum genet  in addition to their utility for improved genetics counseling of patients and their families the global assessment reported here will be invaluable for validation of functional assays structural models and in silico analyses   credits    contact us    privacy notice    disclaimer    faq labomeorg   all rights researvedprinceton new jersey  usalast updated july   firstword medtech login  subscribe saturday july   get unlimited medtech plus subscriptions for one low fixed rate with a firstword medtech country licenseclick here for more details home my newsall my news my companywatch my conditionwatch my marketsegmentwatch my medicalmeetingwatch my productwatch my regulatorywatch all newsexplore latest news all company news all condition news all medical meeting news all product news all market segment news all regulatory market and agency news all therapeutic category news most popularmost popular in the last  hours most popular in the last  days most popular in the last  days storywatchduodenoscope reprocessing in focus emerging markets latest earnings reports pharma alliances product approvals and certifications us vaginalmesh product lawsuits where health meets tech servicesmobile search twitter rss podcasts radio you have reached your maximum article count for the day select your firstword medtech service firstword medtech where people who know first go firstsubscribe to firstword medtech for an overview of top medical technology industry news stories from across the globe in a format that is quick and easy to use firstword medtech plus your news your way subscribe to firstword medtech plus for more indepth medtech news and intelligence with the convenience of user customisation   firstword medtech services available firstword medtech plus services available breaking news yesyes  customisable to your specific preferences top stories yesyes daily email newsletter yesyes  choice of  editions mobile device compatible yesyes podcasts yesyes radio yesyes global coverage yesyes company news restricted accessunlimited access plus monitor up to  different companies of your choice in my companywatch condition news restricted accessunlimited access plus monitor up to  different medical conditions of your choice in my conditionwatch product news restricted accessunlimited access plus monitor up to  different compoundsproducts of your choice in my productwatch regulatory market and agency news restricted accessunlimited access plus monitor up to  markets and related regulatory bodies of your choice in my regulatorywatch medical meeting news restricted accessunlimited access to the medtech conferences listed plus monitor up to  meetings of your choice in mymedical meetingwatch therapeutic category news restricted accessfull access the most popular news items restricted accessfull access story watch restricted accessfull access archive and news search not availablefull access annual subscription freeus  riskfree guarantee we are confident that you will see the benefits of upgrading to firstword medtech plus however if for any reason you are not satisfied with your subscription you may cancel it within  days and receive a full refundif for any reason you are not satisfied with your subscription you may cancel it within  days for a full refundplease feel free to contact us for more information about firstword medtech  refer a colleague  upgrade your firstword medtech  contact firstword medtech  firstword reportsadvertise with firstword medtech  industry partner showcaseall contents copyright   doctors guide publishing limited all rights reservedterms of use  privacy policy myriad genetics  about myriad  inside myriad menu toggle navigation patients and families disease info hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis your questions about disease what’s my risk do i have a disease how aggressive is my disease how should i treat my disease   learn about the quiz genetic testing  genes  disease benefits of genetic testing genetic testing faqs the myriad advantage   view product details the myriad difference the myriad promise financial assistance program customer service your privacy patient resources mysupport™ hereditary cancer quiz real patient stories patient support groups find a healthcare provider available for free on the app store healthcare professionals disease education hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis improving patient care predicting disease diagnosing disease assessing prognosis guiding personalized treatment learn more about genetic testing genetic testing process genetic tests for hereditary cancers genetic testing faqs policy on genetic information financial assistance program view product details professional resources myriadpro hereditary cancer quiz order a test kit myriad lab certificates order a test kit need help myriad customer service myriad    cscommentsmyriadcom learn about the quiz insurance providers myriad managed care decrease costs while improving patient wellbeing learn more » contact us today » lab accuracy accurate test results drive optimal treatments myvision® » databases » accreditations » hereditary cancer » prostate cancer » breast cancer » rheumatoid arthritis » melanoma » mental illness » research partnerships research at myriad view myriad pipeline partnerships  licensing companion diagnostics partnerships other industry partnerships licensing at myriad academic collaborations interested in collaborating with myriad industry partners contact andrew drew gibbs senior director business development myriad genetics inc   dgibbsmyriadcom academic partners contact john gill jd mba senior director business development myriad genetics inc   jgillmyriadcom news center media newsroom media kits executive bios news releases events  presentations ron rogers evp corporate communications   rrogersmyriadcom investor information investor faqs news releases events  presentations financial reporting stock information scott gleason vp investor relations   sgleasonmyriadcom multimedia library videos infographics images media kits view infographic myriad matters blog our policy on patient privacy video – pioneering advances in personalized medicine corporate fact sheet careers at myriad the myriad culture our employees our community our diversity video –  ragnar race joining the myriad team current openings internships employment benefits myriad fact sheet about myriad inside myriad myriad ataglance company fact sheet history executive bios board of directors company milestones myriad around the world global presence international distributors international distributor map locations  directions directions to myriad directions to myriad rbm directions to myriad international directions to assurex health directions to crescendo bioscience myriad cares the myriad pledge the myriad promise corporate social responsibility financial assistance program patient advocacy patient support groups policy on genetic information contact us  myriad   myriad genetics inc  wakara way salt lake city ut  corporate fact sheet inside myriad inside myriad overview myriad ataglance company fact sheet history executive bios board of directors company milestones myriad around the world overview global presence international distributors locations  directions overview directions to myriad directions to myriad rbm directions to myriad international directions to crescendo bioscience directions to assurex health contact us corporate offices international offices about myriad  inside myriad  overview share at myriad our goal is to make a difference in patients’ lives and our work has been guided by this mission throughout the company’s history myriad is focused on revolutionizing patient care through the discovery development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties since  myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease more than  million patients have already benefited from myriad’s hereditary cancer genetic testing which helps healthcare professionals better manage and tailor medical care today myriad continues this strong tradition we are expanding our reach and increasing our impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases we also are focused on expanding internationally in an effort to broaden our geographic footprint and provide our lifesaving products and services to patients and healthcare professionals around the world related informationmyriad ataglancecompany milestonesmyriad around the world myriad fact sheet at myriad we are committed to making products that improve people’s lives hereditary cancer knowing your cancer family history can inform your medical decisions and improve the outcomes of your healthcare terms of use privacy policy data protection and privacy statement site map contact us   myriad genetics  about myriad  management team executive bios menu toggle navigation patients and families disease info hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis your questions about disease what’s my risk do i have a disease how aggressive is my disease how should i treat my disease   learn about the quiz genetic testing  genes  disease benefits of genetic testing genetic testing faqs the myriad advantage   view product details the myriad difference the myriad promise financial assistance program customer service your privacy patient resources mysupport™ hereditary cancer quiz real patient stories patient support groups find a healthcare provider available for free on the app store healthcare professionals disease education hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis improving patient care predicting disease diagnosing disease assessing prognosis guiding personalized treatment learn more about genetic testing genetic testing process genetic tests for hereditary cancers genetic testing faqs policy on genetic information financial assistance program view product details professional resources myriadpro hereditary cancer quiz order a test kit myriad lab certificates order a test kit need help myriad customer service myriad    cscommentsmyriadcom learn about the quiz insurance providers myriad managed care decrease costs while improving patient wellbeing learn more » contact us today » lab accuracy accurate test results drive optimal treatments myvision® » databases » accreditations » hereditary cancer » prostate cancer » breast cancer » rheumatoid arthritis » melanoma » mental illness » research partnerships research at myriad view myriad pipeline partnerships  licensing companion diagnostics partnerships other industry partnerships licensing at myriad academic collaborations interested in collaborating with myriad industry partners contact andrew drew gibbs senior director business development myriad genetics inc   dgibbsmyriadcom academic partners contact john gill jd mba senior director business development myriad genetics inc   jgillmyriadcom news center media newsroom media kits executive bios news releases events  presentations ron rogers evp corporate communications   rrogersmyriadcom investor information investor faqs news releases events  presentations financial reporting stock information scott gleason vp investor relations   sgleasonmyriadcom multimedia library videos infographics images media kits view infographic myriad matters blog our policy on patient privacy video – pioneering advances in personalized medicine corporate fact sheet careers at myriad the myriad culture our employees our community our diversity video –  ragnar race joining the myriad team current openings internships employment benefits myriad fact sheet about myriad inside myriad myriad ataglance company fact sheet history executive bios board of directors company milestones myriad around the world global presence international distributors international distributor map locations  directions directions to myriad directions to myriad rbm directions to myriad international directions to assurex health directions to crescendo bioscience myriad cares the myriad pledge the myriad promise corporate social responsibility financial assistance program patient advocacy patient support groups policy on genetic information contact us  myriad   myriad genetics inc  wakara way salt lake city ut  corporate fact sheet executive bios understanding myriad investor faqs corporate governance executive bios board of directors news releases all financial news corporate news product news pipeline news events  presentations financial scientific financial reporting gaap to nongaap reconciliation sec filings annual reports quarterly results key ratios stock information current share price historic share price investment calculator dividend history analyst coverage about myriad  inside myriad  executive bios mark c caponepresident and ceo mark c capone is president and ceo of myriad genetics he previously served as president of myriad genetic laboratories from march  to june  mr capone joined the company in october  prior to joining myriad he served  years with eli lilly and company where he held positions as product development manager manufacturing plant manager and area sales director mr capone received his bs degree in chemical engineering from penn state university graduating with highest distinction and his ms degree in chemical engineering from massachusetts institute of technology he also earned a master of science in management from the sloan school of management at the massachusetts institute of technology in  mr capone was elected outstanding engineering alumnus at penn state and he is a member of the industrial and professional advisory council at penn state he currently serves on the board of the american clinical laboratory association mr capone also is a member of the board of trustees for pioneer theatre company in salt lake citypatrick burkeexecutive vice president emerging products myriad genetics inc patrick burke executive vice president of emerging products joined the company in  in his current role he oversees new product planning business development and project management previously dr burke served as vice president of strategic collaborations and held positions of increasing responsibility within the business and corporate development group at myriad between  and  he served as vice president of corporate and business development at myrexis inc a subsidiary of the company dr burke is an active member of licensing executive society and the association of university technology managers he earned his phd in cell biology from the university of utah school of medicine and his ba in molecular biology from the university of california san diegovirginia c drosospresident assurex health virginia “gina” c drosos president of assurex health joined the company in  previously she grew global brand portfolios in the consumer goods and personal care industries at procter  gamble for  years  ms drosos was group president for global beauty care a  billion business with  employees in  countries and  brands including covergirl old spice pantene and olay which grew from less than  million to more than  billion in sales under her leadership twice recognized as one of fortune’s  most powerful women in business ms drosos was also recently named  corporate woman of the year by the cincinnati chamber of commerce and one of cincinnati’s “ for ” top business leaders under her leadership assurex health was recognized as one of inc magazine’s  fastest growing womenled companies in america and usa today’s top  entrepreneurial companies  ms drosos  holds a bs in business administration from the terry school university of georgia and an mba from the wharton school university of pennsylvania she serves on the boards of directors of signet jewelers ltd and american financial groupalexander fordpresident myriad genetic laboratories inc alexander ford president of myriad genetic laboratories joined the company in june  before being named to his current position he served as chief commercial officer prior to joining myriad mr ford held leadership positions at novartis sanofiaventis nektar therapeutics and pfizer in the areas of marketing research product marketing managed care sales and business development he has more than  years of experience in the pharmaceutical and biotechnology industries mr ford received his ba degree in communications from the university of north carolina wilmington and his ma degree from new york university  he was a founding board member for bioutah and was voted sales executive of the year by the utah technology council in robert g harrisonchief information officer myriad genetics inc robert g harrison chief information officer joined myriad in  he served as myriads network administrator from  to  and was named director of information systems and technology in  mr harrison was named vice president of information systems and technology in  a position he held until january  when he was named chief information officer he began his career in it working for several private companies and consulting firms where he held positions in technical support sales and management roles mr harrison received a bs degree in business administration with a minor in computer science from the university of utah in jayne b hartexecutive vice president human resources myriad genetics incjayne b hart joined myriad in may  as executive vice president of human resources she has more than twenty years of professional experience in the human resources field prior to joining myriad ms hart served as vice president of human resources at landesk software a global software company before that she was vice president of human resources for networks a wholesale telecommunications company and at att wireless a global telecommunications company where she began her careergary a kingexecutive vice president international operations myriad genetics incgary a king joined myriad in july  he has been employed in the life sciences industry for more than  years most recently he was the chief executive officer of averdx inc an international biotechnology company prior to averdx mr king was vice president of international operations at biosite inc where he spent six years building and leading all of the companys commercial activities outside of the united states he established marketing and logistics operations in germany france italy the united kingdom netherlands and belgium and formed clinical operations and marketing programs in asia prior to joining biosite he was division director in japan for guidant corporation and led guidants transition from distributor to direct operations in the japanese market mr king received his ba degree in zoology from pomona college and an mba degree from stanford universityjerry lanchburychief scientific officer myriad genetics inc jerry lanchbury chief scientific officer joined myriad in september  before that he was a researcher in molecular immunogenetics at kings college london he is a highly respected expert in immunogenetics with more than  reviewed research journal publications dr lanchbury graduated from the university of aston birmingham uk he earned his phd in population genetics from the university of newcastle upon tyne and subsequently completed a postdoctoral fellowship at the united medical  dental schools of the university of london in human disease geneticsrichard marshexecutive vice president general counsel and secretary myriad genetics inc richard marsh executive vice president general counsel and secretary joined myriad in november  prior to that he served in various positions at iomega corporation including acting general counsel director of ip and director of commercial legal affairs mr marsh received an llm degree in taxation from georgetown university law center a law degree from thomas m cooley law school graduating magna cum laude and a bs degree in accounting from brigham young university he was formerly a certified public accountantralph l mcdadepresident myriad rbmralph l mcdade is the president of myriad rbm until august of  he had been serving as chief operating officer dr mcdade was formerly strategic development officer for myriad rbm and held that position since the companys inception in  prior to joining myriad rbm he was chief scientific officer for luminex corporation where he was closely involved with the development of xmap technology in addition dr mcdade was instrumental during this period in securing technology licensing agreements with over  strategic partners he received his phd in microbiology from the university of texas southwestern medical school in  following postdoctoral training at the university of connecticut medical center in farmington he held faculty positions at the rockefeller university in new york and at louisiana state university school of medicine in new orleans paul c parkinsonexecutive vice president reimbursement strategy myriad genetics inc paul “chip” parkinson executive vice president for reimbursement strategy joined the company in   previously he was president of omedarx and chief pharmacy officer of regence blue cross blue shield health plans in this role mr parkinson was responsible for managing  billion in annual pharmacy spending for the regence blue cross blue shield health plans in utah washington oregon and idaho which have more than two million members  prior to that he was vice president managed markets and general manager urology at myriad during his tenure prolaris was included in the nccn guidelines for prostate cancer and received medicare reimbursement before joining myriad he served in management and managed care leadership roles at pfizer inc  mr parkinson received his bs degree in communications from weber state universitybryan riggsbeechief financial officer myriad genetics inc bryan riggsbee chief financial officer joined myriad in october  he previously served  years with laboratory corporation of america labcorp where his most recent position was as senior vice president of corporate finance with responsibility for the financial planning and analysis and treasury functions prior to labcorp mr riggsbee served in various finance roles with general electric and began his career in the audit division of kpmg he received a ba in accounting from north carolina state university a ba in political science from the university of north carolina at chapel hill and an mba from northwestern university mr riggsbee is a certified public accountant licensed in the state of north carolinaronald rogersexecutive vice president corporate communications myriad genetics incronald rogers executive vice president of corporate communications joined myriad in april  he previously served as executive director of global media relations at merck  co mr rogers also worked in communications roles at johnson  johnson hoechst marion roussel eli lilly and searle and was a business reporter at chemical  engineering news he received an ms degree in communications and a bs degree in public relationschemistry from illinois state university he is a member of the national association of science writersbernard f tobinpresident crescendo bioscience inc bernard tobin president of crescendo bioscience joined myriad in january  he previously held several senior positions at amgen including executive director of national accounts general manager of both the netherlands and brazil and global head of commercial excellence in addition he led the global integration of a business development acquisition in more than  countries prior to that mr tobin held a variety of leadership roles in the commercial organization at eli lilly and co he received his bs degree in public service and administration from iowa state university and his mba from the fuqua school of business duke universityrichard j wenstrupchief medical officer myriad genetics inc richard j wenstrup chief medical officer joined myriad in  as chief medical officer for myriad genetic laboratories where he led the clinical affairs and corporate medical services departments  prior to joining myriad he was internationally recognized for his academic research in heritable disorders of connective tissue and the skeleton and served as a tenured professor of pediatrics human genetics at cincinnati children’s hospital and professor of biomedical engineering at the university of cincinnati  dr wenstrup has published more than  peerreviewed papers on human and mouse genetics  he served as past president of the medical advisory board of the ehlersdanlos national foundation and at the osteogenesis imperfecta foundation oif and as chair of the scientific advisory board of the oif   he currently is a member of the scientific advisory board of the marfan foundation dr wenstrup received his medical degree from the university of cincinnati college of medicine and completed a pediatrics residency at the university of minnesota hospital and a fellowship in medical genetics at the university of washington media contact ron rogers evp corporate communications   rrogersmyriadcom learn how prolaris personalizes prostate cancer treatment stock quotenasdaqmygn  intraday high   week high  intraday low   week low  volume   pm est on jul  delayed at least  minutesprovided by esignal personalizing prostate cancer treatment prolaris measures cancer aggressiveness to help personalize treatment for men with prostate cancer widgetized area  add widget texthtml via the wp admin using newsroomrightarea terms of use privacy policy data protection and privacy statement site map contact us   richard j wenstrup  chief medical officer at oxford immunotec global plc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink richard j wenstrup chief medical officer at oxford immunotec global plc overview in the news relationships paths family members education career history boards  committees public holdings richard j wenstrup chief medical officer at oxford immunotec global plc overview age  born  board seats  number of relationships this person is connected to  people in the news see more fiercebiotech july   chutes  ladders—biogen lures novartis exec to lead us marketing activities relsci july   richard j wenstrup is now serving in a new position at oxford immunotec global plc globenewswire july   oxford immunotec appoints richard wenstrup md as chief medical officer cincinnati business courier june   assurex health to move headquarters cincinnati business courier december   exclusive employee no  departing assurex health see full news coverage and complete stories with relsci professional create your news feed see more relationships see details karen k christian psychiatrist at intermountain healthcare inc michael l weamer president  chief executive officer at national marfan foundation inc craig t basson chair scientific advisory board at national marfan foundation inc john a elefteriades director of aortic institute at yale university peter h byers member professional advisory board at national marfan foundation inc jonathan w weinsaft member scientific advisory board at national marfan foundation inc jil c tardiff member scientific advisory board at national marfan foundation inc scott a lemaire professor  vice chair for research at baylor college of medicine joseph lorenzo member scientific advisory board at national marfan foundation inc b timothy baxter member scientific advisory board at national marfan foundation inc see  more listings with relsci professional start my free trial ➤ see  more paths to richard j wenstrup richard j wenstrup you connections via relationship science richard j wenstrup sync your contacts to see how you can connect with richard j wenstrup start my free trial ➤ see more family members child nathaniel wenstrup attorney at the bronx defenders to bring justice for people living in the bronx by transforming the role of public defenders childinlaw rebecca jane livengood clerk at us court of appeals for the third circuit spouse karen k christian psychiatrist at intermountain healthcare inc intermountain health care inc provides healthcare services it offers flu vaccination cancer treatment urgent care behavioral health medicalsurgical intensive care acute care emergency diagnostic imaging and radiology labor and delivery long term care critical care homecare and hospice sleep laboratory women and newborn care cardiovascular medicine inpatient and outpatient care trauma and emergency medicine pulmonary care wellness children care homecare and medical equipment respiratory therapy speech pathology orthopedic surgical care sports performance training nutrition counseling and infusion therapy services the company was founded on april   and is headquartered in salt lake city ut educational background   the university of cincinnati college of medicine career history chief medical officer   current oxford immunotec global plc oxford immunotec global plc is a medical diagnostics company which engages in the developing and commercializing of proprietary tests for underserved immuneregulated conditions its current product lines and development activities principally focus on four areas infectious diseases transplantation autoimmune and inflammatory disease and immuneoncology the company was founded in  and is headquartered in abingdon the united kingdom chief medical officer   prior myriad genetics inc our goal at myriad is to make a difference in patient’s lives and for the past twenty years the company’s strategy has been guided by this mission to accomplish this we are focused on revolutionizing patient care through the development and marketing of transformative tests which address pressing clinical needs across multiple medical specialties over the last twenty years myriad has invested heavily in the education of patients and health care providers on the role genes and their related proteins play in disease almost one million patients have already benefited from myriad’s informative testing which helps physicians better manage their health care today myriad continues to build on this strong tradition we are working to expand our reach by introducing new genetic tests and molecular diagnostic tests for a number of diseases we also are focused on extending our mission internationally in an effort to broaden our geographic footprint and provide critical information to more patients and healthcare providers chief medical officer prior myriad genetic laboratories inc myriad genetic laboratories inc provides cancer predisposition testing services it operates as a biopharmaceutical company that focuses on developing therapeutic and predictive medicine products the company was founded on october   and is headquartered in salt lake city ut professor prior university of cincinnati  ohio university of cincinnati is a comprehensive public research university in cincinnati in the us state of ohio and a part of the university system of ohio founded in  as cincinnati college it is the oldest institution of higher education in cincinnati and has an annual enrollment of over  students making it the second largest university in ohio and one of the largest universities in the united states professor prior cincinnati childrens hospital medical center cincinnati childrens hospital medical center provides health care services for childrens it offers clinical services from treatments for rare and complex conditions to wellchild care and education and training and research services the firms services include transplants of hearts blood and marrow livers kidneys and small bowel the company was founded in  and is headquartered in cincinnati oh boards  committees nonprofit boards ▾ member scientific advisory board current national marfan foundation inc the marfan foundation creates a brighter future for everyone affected by marfan syndrome and related disorders we pursue the most innovative research and make sure that it receives proper funding we inform the public and educate the patient community to increase early diagnosis and ensure lifesaving treatment we provide relentless support to families caregivers and healthcare providers we will not rest until we have achieved victory in a world in which everyone with marfan syndrome or a related disorder receives a proper diagnosis gets the necessary treatment and lives a long and full life public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations richard j wenstrup is affiliated with oxford immunotec global plc myriad genetics inc myriad genetic laboratories inc university of cincinnati  ohio cincinnati childrens hospital medical center national marfan foundation inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ myriad genetics  about myriad  inside myriad menu toggle navigation patients and families disease info hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis your questions about disease what’s my risk do i have a disease how aggressive is my disease how should i treat my disease   learn about the quiz genetic testing  genes  disease benefits of genetic testing genetic testing faqs the myriad advantage   view product details the myriad difference the myriad promise financial assistance program customer service your privacy patient resources mysupport™ hereditary cancer quiz real patient stories patient support groups find a healthcare provider available for free on the app store healthcare professionals disease education hereditary breast cancer hereditary colon cancer hereditary endometrial cancer lung cancer melanoma hereditary ovarian cancer hereditary pancreatic cancer prostate cancer rheumatoid arthritis improving patient care predicting disease diagnosing disease assessing prognosis guiding personalized treatment learn more about genetic testing genetic testing process genetic tests for hereditary cancers genetic testing faqs policy on genetic information financial assistance program view product details professional resources myriadpro hereditary cancer quiz order a test kit myriad lab certificates order a test kit need help myriad customer service myriad    cscommentsmyriadcom learn about the quiz insurance providers myriad managed care decrease costs while improving patient wellbeing learn more » contact us today » lab accuracy accurate test results drive optimal treatments myvision® » databases » accreditations » hereditary cancer » prostate cancer » breast cancer » rheumatoid arthritis » melanoma » mental illness » research partnerships research at myriad view myriad pipeline partnerships  licensing companion diagnostics partnerships other industry partnerships licensing at myriad academic collaborations interested in collaborating with myriad industry partners contact andrew drew gibbs senior director business development myriad genetics inc   dgibbsmyriadcom academic partners contact john gill jd mba senior director business development myriad genetics inc   jgillmyriadcom news center media newsroom media kits executive bios news releases events  presentations ron rogers evp corporate communications   rrogersmyriadcom investor information investor faqs news releases events  presentations financial reporting stock information scott gleason vp investor relations   sgleasonmyriadcom multimedia library videos infographics images media kits view infographic myriad matters blog our policy on patient privacy video – pioneering advances in personalized medicine corporate fact sheet careers at myriad the myriad culture our employees our community our diversity video –  ragnar race joining the myriad team current openings internships employment benefits myriad fact sheet about myriad inside myriad myriad ataglance company fact sheet history executive bios board of directors company milestones myriad around the world global presence international distributors international distributor map locations  directions directions to myriad directions to myriad rbm directions to myriad international directions to assurex health directions to crescendo bioscience myriad cares the myriad pledge the myriad promise corporate social responsibility financial assistance program patient advocacy patient support groups policy on genetic information contact us  myriad   myriad genetics inc  wakara way salt lake city ut  corporate fact sheet inside myriad inside myriad overview myriad ataglance company fact sheet history executive bios board of directors company milestones myriad around the world overview global presence international distributors locations  directions overview directions to myriad directions to myriad rbm directions to myriad international directions to crescendo bioscience directions to assurex health contact us corporate offices international offices about myriad  inside myriad  overview share at myriad our goal is to make a difference in patients’ lives and our work has been guided by this mission throughout the company’s history myriad is focused on revolutionizing patient care through the discovery development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties since  myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease more than  million patients have already benefited from myriad’s hereditary cancer genetic testing which helps healthcare professionals better manage and tailor medical care today myriad continues this strong tradition we are expanding our reach and increasing our impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases we also are focused on expanding internationally in an effort to broaden our geographic footprint and provide our lifesaving products and services to patients and healthcare professionals around the world related informationmyriad ataglancecompany milestonesmyriad around the world myriad fact sheet at myriad we are committed to making products that improve people’s lives hereditary cancer knowing your cancer family history can inform your medical decisions and improve the outcomes of your healthcare terms of use privacy policy data protection and privacy statement site map contact us   richard j wenstrup is now serving in a new position at oxford immunotec global plc news home advertising board and executive moves energy health care hedge funds m  a private equity technology see more news on board and executive moves richard j wenstrup is now serving in a new position at oxford immunotec global plc email linkedin facebook google tweet reddit permalink jul    relsci data update board and executive moves background information richard j wenstrup » chief medical officer at oxford immunotec global plc career oxford immunotec global plc myriad genetics inc myriad genetic laboratories inc boards national marfan foundation inc education the university of cincinnati college of medicine in the news oxford immunotec appoints richard wenstrup md as chief medical officer july    •  globenewswire assurex health to move headquarters june    •  cincinnati business courier exclusive employee no  departing assurex health december    •  cincinnati business courier richard j wenstrup » chief medical officer at oxford immunotec global plc career • oxford immunotec global plc • myriad genetics inc • myriad genetic laboratories inc boards • national marfan foundation inc education • the university of cincinnati college of medicine in the news oxford immunotec appoints richard wenstrup md as chief medical officer  july    •  globenewswire assurex health to move headquarters  june    •  cincinnati business courier exclusive employee no  departing assurex health  december    •  cincinnati business courier oxford immunotec global plc » oxford immunotec global plc is a medical diagnostics company which engages in the developing and commercializing of proprietary tests for underserved immuneregulated conditions its current product lines and development activities principally focus on four areas infectious diseases transplantation autoimmune and inflammatory disease and immuneoncology the company was founded in  and is headquartered in abingdon the united kingdom in the news karen koski is now serving in a new position at oxford immunotec global plc july    •  relsci oxford immunotec receives reimbursement for tuberculosis screening from ministry of health and social affairs june    •  marketline newswire oxford immunotec announces national reimbursement for the tspotâ®tb test in france june    •  globenewswire oxford immunotec global plc » oxford immunotec global plc is a medical diagnostics company which engages in the developing and commercializing of proprietary tests for underserved immuneregulated conditions its current product lines and development activities principally focus on four areas infectious diseases transplantation autoimmune and inflammatory disease and immuneoncology the company was founded in  and is headquartered in abingdon the united kingdom in the news karen koski is now serving in a new position at oxford immunotec global plc  july    •  relsci oxford immunotec receives reimbursement for tuberculosis screening from ministry of health and social affairs  june    •  marketline newswire oxford immunotec announces national reimbursement for the tspotâ®tb test in france  june    •  globenewswire see more news on board and executive moves youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ dr richard wenstrup pediatrics  cincinnati  oh  sharecare ask a health related question join sharecare log in find a doctor health experts topics video health tools profile locations more find a doctor  pediatrics  oh  cincinnati  dr richard wenstrup md dr richard wenstrup pediatrics cincinnati oh male  years of experience  insurance plans languages supported at his practice italian vietnamese english french russian arabic spanish accepting new patients electronic health records treats children dr wenstrups background bio richard j wenstrup md is a practicing pediatrician in cincinnati oh dr wenstrup graduated from university of cincinnati college of medicine in  and has been in practice for  years he completed a residency at university of washington medical center dr wenstrup accepts multiple insurance plans including humana dr wenstrup is board certified in clinical genetics in addition to english dr wenstrups practice supports these languages italian vietnamese french russian arabic and spanish specialties pediatrics education residency university of washington medical center medical school  university of cincinnati college of medicine cincinnati oh learn more about pediatrics article see all articles  er urgent care or physician  know where to go whether it’s a bump on the head or a really bad cold when your body suffers a blow all you want to do is feel better but where do you go to get the care you need next time you experience a nasty fall or read more questions see all questions  what testing is needed for children with a family history of scoliosis how do i know if my child needs surgery for scoliosis primary location  burnet ave cincinnati oh  see all locations phone number have you visited dr wenstrup before yes no   similar doctors dr kareen jones pediatrics  burnet ave cincinnati oh  dr seth gray pediatrics  burnet ave cincinnati oh  dr nafeh fananapazir pediatrics  burnet ave cincinnati oh  dr todd florin pediatrics  burnet ave cincinnati oh  dr paige hamilton pediatrics  burnet ave cincinnati oh